@article{oai:tsukuba.repo.nii.ac.jp:00044645,
 author = {沖山, 奈緒子 and 小川, 健 and 渡邉, 玲 and 藤本, 学 and Koguchi-Yoshioka, H. and Okiyama, N. and Iwamoto, K. and Matsumura, Y. and Ogawa, T. and Inoue, S. and Watanabe, R. and Fujimoto, M.},
 issue = {5},
 journal = {British journal of dermatology},
 month = {Nov},
 note = {Autoantibodies to melanoma differentiation-associated protein 5 (MDA5) are associated with a subset of patients with dermatomyositis (DM) who have rapidly progressive interstitial lung disease (RP-ILD) with poor prognosis. Intensive immunosuppressive therapy is initiated before irreversible lung damage can occur; however, there are few lines of evidence for the treatment of RP-ILD. Here, we report three cases of anti-MDA5 antibody-associated DM with RP-ILD in which the patients were treated with combined-modality therapy, including high-dose prednisolone, tacrolimus, intravenous cyclophosphamide and intravenous immunoglobulin (IVIG). In all three cases, serum ferritin levels, which are known to represent the disease activity of RP-ILD, were decreased after IVIG administration. IVIG might contribute to the control of the disease activity of anti-MDA5 antibody-positive DM. Moreover, palmar violaceous macules/papules around the interphalangeal joints, which was observed in all three cases in the incipient stage, might be a useful sign in suggesting a diagnosis of anti-MDA5 antibody-associated DM.},
 pages = {1442--1446},
 title = {Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules},
 volume = {177},
 year = {2017}
}